Moleculin authorizes reverse split: what it means for Moleculin Biotech stock
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Moleculin Biotech's board has authorized a reverse stock split at a ratio from 1-for-2 to 1-for-20, which can be executed before October 9, 2027. This decision, along with an increase in the company's stock plan by 3,861,894 shares, provides Moleculin with flexibility in its share structure and financing capacity.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.